Product
Pasireotide
Name
Signifor
FDA Approved
Yes
3 clinical trials
1 organization
3 indications
2 documents
Indication
HypoglycemiaIndication
Peritoneal CarcinomatosisIndication
Prolactin-Producing Pituitary TumorClinical trial
A Double-blind Randomized Placebo-controlled Dose-finding Phase II Study to Assess the Efficacy and Safety of Pasireotide s.c. in Patients With Post-Bariatric HypoglycaemiaStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Efficacy and Feasibility of Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis - a Phase II Randomized Multicentric TrialStatus: Terminated, Estimated PCD: 2024-02-07
Clinical trial
Pasireotide Treatment for Patients With Prolactinomas Who Need Treatment Beyond Dopamine Agonist TherapyStatus: Recruiting, Estimated PCD: 2027-02-01
Document
DailyMed Label: SigniforOrganization
Recordati Rare Diseases, Inc.Document
DailyMed Label: Signifor LAR